{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:16:19Z","timestamp":1791994579070,"version":"4.4.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T00:00:00Z","timestamp":1634169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2020J02053, 2020J01966"],"award-info":[{"award-number":["2020J02053, 2020J01966"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Bullous pemphigoid (BP) is an autoimmune blistering disorder that predominantly affects the elderly. As the main treatment for BP, systemic corticosteroids are often limited by their side effects. Safer treatment modalities are therefore needed. Dupilumab is a biologic agent used to treat BP in recent years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Medical records of patients with moderate-to-severe BP were retrospectively reviewed. Twenty-four patients were included (follow-up period: 32\u00a0weeks), eight of whom received dupilumab in combination with methylprednisolone and azathioprine (dupilumab group) while the other 16 patients received methylprednisolone and azathioprine (conventional group). Response to dupilumab was evaluated by comparison of several parameters (time to stop new blister formation, time to reduce the systemic glucocorticoids to minimal dose, and total amount of methylprednisolone).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median age of patients in the dupilumab and conventional groups were 64.50\u00a0years (range: 22\u201390\u00a0years) and 64.50\u00a0years (range: 17\u201386\u00a0years), respectively. The median duration of disease before admission in the dupilumab group was 2\u00a0months (range: 1\u2013240\u00a0months) and 2.5\u00a0months (range: 1\u201360\u00a0months) in the conventional group. The median time to stop new blister formation was 8\u00a0days (range: 1\u201313\u00a0days) and 12\u00a0days (range: 5\u201321\u00a0days) in patients of the dupilumab and conventional groups, respectively (<jats:italic>p<\/jats:italic>\u00a0=\u00a00.028 by Kaplan-Meier analysis). In addition, the median time to reduce the systemic glucocorticoids to minimal dose (methylprednisolone 0.08\u00a0mg\/kg\/day) was 121.5 and 148.5\u00a0days for the dupilumab and conventional therapy groups, respectively (<jats:italic>p<\/jats:italic>\u00a0=\u00a00.0053 by Kaplan-Meier analysis). The median total amount of methylprednisolone (at the time of reaching the minimal dose) used in the dupilumab group was 1,898\u00a0mg (range: 1,624\u20132,932\u00a0mg) while the cumulative dose of conventional group was 2,344\u00a0mg (range: 1,708\u20134,744\u00a0mg) (<jats:italic>p<\/jats:italic>\u00a0=\u00a00.036 by Mann-Whitney <jats:italic>U<\/jats:italic> test). The median total amount of azathioprine (at the time of reaching the minimal dose) used in dupilumab group was 8,300\u00a0mg (range:\u00a07,100\u201310,400\u00a0mg) while the total dose of conventional group was 10,300\u00a0mg (range: 8,900\u201314,400\u00a0mg) (<jats:italic>p<\/jats:italic>\u00a0=\u00a00.0048 by Mann-Whitney <jats:italic>U<\/jats:italic> test). No adverse event related to dupilumab was recorded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Dupilumab in addition to methylprednisolone and azathioprine seems superior to methylprednisolone\/azathioprine alone in controlling disease progression and accelerating the tapering of glucocorticoids.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2021.738907","type":"journal-article","created":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T09:38:11Z","timestamp":1634204291000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":73,"title":["Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid"],"prefix":"10.3389","volume":"12","author":[{"given":"Yihua","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2008.04.012","article-title":"Multicenter Prospective Study of the Humoral Autoimmune Response in Bullous Pemphigoid","volume":"128","author":"Di Zenzo","year":"2008","journal-title":"Clin Immunol (Orlando Fla.)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09300.x","article-title":"Incidence of Bullous Pemphigoid and Pemphigus in Switzerland: A 2-Year Prospective Study","volume":"161","author":"Marazza","year":"2009","journal-title":"Br J Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2009.04345.x","article-title":"Pemphigus Vulgaris Is the Most Common Autoimmune Bullous Disease in Northwestern Romania","volume":"49","author":"Baican","year":"2010","journal-title":"Int J Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"a180","DOI":"10.1136\/bmj.a180","article-title":"Bullous Pemphigoid and Pemphigus Vulgaris\u2013Incidence and Mortality in the UK: Population Based Cohort Study","volume":"337","author":"Langan","year":"2008","journal-title":"BMJ (Clinical Res ed.)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20199007","article-title":"Bullous Pemphigoid","volume":"94","author":"Miyamoto","year":"2019","journal-title":"Anais brasileiros dermatologia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s12016-017-8633-4","article-title":"Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management","volume":"54","author":"Amber","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15679","article-title":"Review of Autoimmune Blistering Diseases: The Pemphigoid Diseases","volume":"33","author":"Daniel","year":"2019","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1172\/jci3335","article-title":"Identification and Characterization of Autoreactive T Cell Responses to Bullous Pemphigoid Antigen 2 in Patients and Healthy Controls","volume":"102","author":"B\u00fcdinger","year":"1998","journal-title":"J Clin Invest"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1578-2190(08)70288-9","article-title":"Practical Management of the Most Common Autoimmune Bullous Diseases","volume":"99","author":"Su\u00e1rez-Fern\u00e1ndez","year":"2008","journal-title":"Actas Dermo-Sifiliograficas"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10748.x","article-title":"Successful Management of Severe Infant Bullous Pemphigoid With Omalizumab","volume":"166","author":"Dufour","year":"2012","journal-title":"Br J Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2012.1604","article-title":"Successful Treatment of Bullous Pemphigoid With Omalizumab","volume":"148","author":"London","year":"2012","journal-title":"Arch Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.11.035","article-title":"Pathogenicity of IgE in Autoimmunity: Successful Treatment of Bullous Pemphigoid With Omalizumab","volume":"123","author":"Fairley","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.04.053","article-title":"Omalizumab Therapy for Bullous Pemphigoid","volume":"71","author":"Yu","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2018.12.015","article-title":"IgE Blockade in Autoimmunity: Omalizumab Induced Remission of Bullous Pemphigoid","volume":"198","author":"James","year":"2019","journal-title":"Clin Immunol (Orlando Fla.)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2010.03889.x","article-title":"Bullous and Mucous Membrane Pemphigoid Show a Mixed Response to Rituximab: Experience in Seven Patients","volume":"25","author":"Lourari","year":"2011","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.07.032","article-title":"Rituximab for Treatment-Refractory Pemphigus and Pemphigoid: A Case Series of 17 Patients","volume":"65","author":"Kasperkiewicz","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.0091","article-title":"Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid","volume":"153","author":"Sowerby","year":"2017","journal-title":"JAMA Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2020.01.089","article-title":"Dupilumab as a Novel Therapy for Bullous Pemphigoid: A Multicenter Case Series","volume":"83","author":"Abdat","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"13030\/qt25q9w6r9","DOI":"10.5070\/D32511046147","article-title":"Dupilumab for Bullous Pemphigoid With Intractable Pruritus","volume":"25","author":"Seidman","year":"2019","journal-title":"Dermatol Online J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.2526","article-title":"Dupilumab for the Treatment of Recalcitrant Bullous Pemphigoid","volume":"154","author":"Kaye","year":"2018","journal-title":"JAMA Dermatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.611549","article-title":"Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid","volume":"11","author":"Seyed Jafari","year":"2020","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0768-3","article-title":"Dupilumab: First Global Approval","volume":"77","author":"Shirley","year":"2017","journal-title":"Drugs"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15111","article-title":"Japanese Guidelines for the Management of Pemphigoid (Including Epidermolysis Bullosa Acquisita)","volume":"46","author":"Ujiie","year":"2019","journal-title":"J Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.06.032","article-title":"Definitions and Outcome Measures for Bullous Pemphigoid: Recommendations by an International Panel of Experts","volume":"66","author":"Murrell","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12065","article-title":"Mortality of Bullous Pemphigoid in the First Year After Diagnosis: A Retrospective Study in a Spanish Medical Centre","volume":"28","author":"Gual","year":"2014","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12806","article-title":"Mortality of Bullous Pemphigoid in Singapore: Risk Factors and Causes of Death in 359 Patients Seen at the National Skin Centre","volume":"170","author":"Cai","year":"2014","journal-title":"Br J Dermatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.05.006","article-title":"Mortality of Patients With Bullous Pemphigoid in Korea","volume":"71","author":"Lee","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2013.01.006","article-title":"Bullous Pemphigoid: Etiology, Pathogenesis, and Inducing Factors: Facts and Controversies","volume":"31","author":"Lo Schiavo","year":"2013","journal-title":"Clinics Dermatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jaad.2019.07.060","article-title":"Pathophysiologic Mechanisms of Itch in Bullous Pemphigoid","volume":"83","author":"Hashimoto","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/08820139.2020.1832113","article-title":"Association Between TH2 Cytokine Gene Polymorphisms and Risk of Bullous Pemphigoid","author":"Tabatabaei-Panah","year":"2020","journal-title":"Immunol investigations"},{"key":"B31","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.jaad.2017.12.022","article-title":"Dupilumab: A Review of Its Use in the Treatment of Atopic Dermatitis","volume":"78","author":"Gooderham","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2016.1140743","article-title":"Long-Term Side Effects of Glucocorticoids","volume":"15","author":"Oray","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(94)90333-6","article-title":"The Effects of Glucocorticoids on Human Eosinophils","volume":"94","author":"Schleimer","year":"1994","journal-title":"J Allergy Clin Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"13030\/qt0dv3f9h6","DOI":"10.5070\/D3274053155","article-title":"Successful Treatment of Bullous Pemphigoid With Dupilumab: A Case and Brief Review of the Literature","volume":"27","author":"Saleh","year":"2021","journal-title":"Dermatol Online J"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.738907\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T09:38:14Z","timestamp":1634204294000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.738907\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,14]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2021.738907"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.738907","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,14]]},"article-number":"738907"}}